% 0期刊文章%乔伊斯·克莱默%一个凯瑟琳Anastassopoulos富尔顿维% % T . Christopher债券% Xuezhe王%大卫·布卢姆%一个旧金山罗查琼娜Moreira % % T Eslicarbazepine醋酸与减少发作严重程度除了减少发作频率(P2.031) % D J神经病学2016% % P P2.031 X % V % 86% N 16补充目的:检查的效果辅助Eslicarbazepine醋酸(ESL)发作严重程度和bothersomeness。首页背景:在第三阶段,随机、双盲试验(093 - 304),难治性部分性癫痫发作的患者,接受兼职ESL(800毫克或1200 mg QD),明显比接受安慰剂的患者更大的发作频率减少。发作严重程度调查问卷(SSQ),设计用于多维patient-reported评估在临床研究中,在基线管理,14周(两周滴定,12周的维护)三个治疗武器。方法:SSQ总分(TS)和域分数(征兆之前发作的频率和乐于助人[b],严重程度和发作的运动bothersomeness在癫痫(DS)和改变意识,认知、情感、和物理方面的postictal复苏后癫痫[是],和总体严重程度和bothersomeness[…])按方案计算的人口(n = 547)。协方差分析模型、调整基线SSQ分数,估计最小二乘方法(lsm)为每个手臂在14周。LSM差异三个武器相比,建立最小临床意义差异(MCIDs)。结果:总体而言,441年(81.1 [percnt])患者有效SSQ TS在基线和周14。一周14 LSM TS比安慰剂显著降低了ESL 1200毫克(2.68 vs 3.20, p < 0.001),与LSM差异(0.52)的MCID超过0.48。lsm也显著降低对ESL 1200毫克DS (3.05 vs 3.46, p = 0.027),因为(1.95 vs 2.51, p = 0.019),和某人(3.09 vs 3.65, p < 0.001)的差异和某人的MCIDs超过0.39和0.48,分别。ESL 800毫克,TS, DS,和某人低于安慰剂; however, only SB was significant (3.28 vs. 3.65, p=0.013). CONCLUSIONS: In this post hoc analysis, ESL-treated patients had significantly less seizure severity and bothersomeness than placebo patients. Disclosure: Dr. Cramer has received personal compensation for activities with Bial, Eisai Inc., Sepracor, UCB Pharma, and Sunovion as a consultant. Dr. Velez has received personal compensation for activities with Sunovion as an employee. Dr. Anastassopoulos has received personal compensation for activities with Covance as an employee. Dr. Bond has nothing to disclose. Dr. Wang has received personal compensation for activities with Covance as an employee. Dr. Blum has received personal compensation for activities with Sunovion Pharmaceuticals Inc. as an employee. Dr. Moreira has received personal compensation for activities with BIAL. Dr. Rocha has received personal compensation for activities with Bial as an employee.Sunday, April 17 2016, 8:30 am-5:30 pm %U